Biomarker-based strategies to assess human exposure to mycotoxins have gained increased acceptance in recent years. In this study, an improved method based on UPLC-MS/MS following 96-well μElution solid-phase extraction was developed and validated for the sensitive and high-throughput determination of zearalenone (ZEN) and its five metabolites α-zearalenol (α-ZEL), β-zearalenol (β-ZEL), α-zearalanol (α-ZAL), β-zearalanol (β-ZAL), and zearalanone (ZAN) in human urine samples, using 13 C-ZEN as an internal standard for accurate quantification. Two plates of samples (n = 192) could be processed within 2 h, and baseline separation of all the analytes was achieved in a total runtime of 6 min. The proposed method allowed ZEN and its metabolites to be sensitively determined in a high-throughput way for the first time, and with significantly improved efficiency and accuracy with respect to existing methods. The limits of detection (LODs) and limits of quantitation (LOQs) ranged from 0.02 to 0.06 ng mL −1 and from 0.05 to 0.2 ng mL −1
Introduction
Zearalenone (ZEN) is a naturally existing estrogenic mycotoxin produced mainly by Fusarium graminearum, Fusarium culmorum, Fusarium equiseti, and Fusarium sacchari [1, 2] .
It commonly occurs in various cereal crops and processed grains, and can also be found in animal-derived food as a consequence of carryover from contaminated feeds. While ZEN is of low acute toxicity, there are major concerns about its estrogenic effects, which can have an adverse impact on the genital organs and reproductive systems of mammalian species [2] [3] [4] [5] . In this regard, JECFA set the provisional maximum tolerable daily intake (PMTDI) for ZEN at 0.5 μg/kg bw/day [6] , while EFSA defined the tolerable daily intake (TDI) of ZEN as 0.25 μg/kg bw/day [7] . Using these health-based guidance values (HBGVs) as well as their own food consumption databases, many organizations and countries have established maximum limits for ZEN in food that range from 30 to 1000 μg/kg [8, 9] .
After oral administration, ZEN is rapidly absorbed and subsequently degraded primarily into α-zearalenol (α-ZEL) and β-zearalenol (β-ZEL) [1, 10, 11] , which undergo further reduction to α-zearalanol (α-ZAL) and β-zearalanol (β-ZAL) [12, 13] . The α-ZAL is metabolized into its isomer β-ZAL and, to a lesser extent, into zearalanone (ZAN) [14] . These metabolites are partially conjugated with sulfonic or glucuronic acid and excreted in the urine [3] .
Humans are easily exposed to ZEN through their diet [15] . Evaluations of exposure levels have traditionally been performed based on occurrence data in combination with consumption data [16] [17] [18] [19] . More recently, considering the heterogeneous distribution of mycotoxins in foodstuffs [20] and probable insufficient data of the used consumption databases [21] , biomarker-based approaches have been proposed and are gaining increasing acceptance. By directly monitoring the presence of ZEN and its metabolites in human physiological samples, it is possible to obtain the actual exposure of an individual or a subgroup of a population, thereby facilitating improved comprehensive assessment [22] . In this context, the development of analytical methods in response to current needs is strongly recommended.
Various approaches to the analysis of ZEN and ZEN metabolites have been established for biological samples, including methods based on high-performance liquid chromatography (HPLC) [23] [24] [25] [26] , gas chromatography-mass spectrometry (GC-MS) [27] , liquid chromatography-mass spectrometry (LC-MS) [28] , and liquid chromatography-tandem mass spectrometry (LC-MS/MS) [29] [30] [31] [32] [33] [34] . Among these methods, LC-MS/MS has increasingly become the preferred technique due to its high sensitivity and selectivity, and it has provided satisfactory performance when used to test human urine samples. Nevertheless, some of the applications limited their determination to only ZEN [33] or its major metabolites (α-ZEL and β-ZEL) [35] [36] [37] . In addition, since ZEN and its metabolites are easily conjugated with glucuronic acid in vivo, some studies have focused on developing LC-MS/MS methods that can detect the resulting conjugates, i.e., ZEN-14-glucuronic acid (ZEN-14-GlcA), ZAN-14-GlcA, and α/β-ZEL-14-GlcA [38, 39] . However, the relatively low sensitivity of these methods to the conjugates (LOQ: 1~25 ng/mL) has greatly hindered the practical use of these methods for the detection of urinary biomarkers at environmentally relevant concentrations. As a consequence, an alternative strategy has been developed that involves measuring the total (free + conjugated) amount of each analyte after enzymatic deconjugation. There have been some recent reports of the determination of ZEN and its five metabolites in human urine through the application of enzymatic hydrolysis, sample extraction/cleanup, and UPLC-MS/MS quantification [30, 34] . This approach permitted a large increase in sensitivity, but the labor-intensive and time-consuming nature of the preparation procedures (e.g., liquid-liquid extraction, the use of solid-phase extraction (SPE) columns, and the need for evaporation and reconstitution steps) has limited its application to large-scale sample analysis.
To address this issue, in the work described in the present paper, a 96-well μElution plate was introduced for the first time to facilitate the simultaneous preparation of multiple samples while reducing the amount of solvent consumed. Therefore, this paper presents a sensitive and highthroughput method for the determination of ZEN and its five metabolites (total or free) in human urine samples by UPLC-MS/MS in combination with a PRiME HLB 96-well μElution plate that enabled simultaneous multisample processing. Within a total run time of 6 min, ZEN and its metabolites were baseline separated, highly enhancing the selectivity of the method. After being validated according to the guidelines defined by the EMEA [40] and FDA [41] , the developed method was employed for the analysis of 301 human urine samples collected from healthy individuals in China. Its high throughput, sensitivity, and accuracy suggest that the proposed method could be a powerful tool for large-scale analysis in ZENrelated toxicokinetic studies, biosurveillance, and exposure risk assessment.
Methods

Chemicals and materials
Certificated standard solutions of ZEN (100 μg/mL), α-ZEL (10 μg/mL), β-ZEL (10 μg/mL), ZAN (10 μg/mL), α-ΖAL (10 μg/mL), β-ZAL (10 μg/mL), and 13 C 18 -ZEN (3 μg/mL) were purchased from Biopure (Tulln, Austria) and stored at −40°C in the dark. β-Glucuronidase (from E. coli) was from Sigma-Aldrich (St. Louis, MO, USA). Acetonitrile, methanol, ammonia acetate, formic acid, and acetic acid were of LC/MS grade (Fisher Scientific, Loughborough, UK). All other chemicals were of analytical grade or better. The deionized water (18.2 MΩ cm) was collected from a Milli-Q system (Millipore Corp., Bedford, MA, USA). The Oasis PRiME HLB 96-well μElution plate (3 mg of sorbent in each well) was obtained from Waters (Milford, MA, USA). A mixed standard solution containing 1 μg/mL of each analyte was prepared in acetonitrile and stored at 4°C in the dark, and remained stable for at least 6 months. Working dilutions of mixed standards were prepared on each day that measurements were performed. The enzyme solution was prepared fresh on the day of use by dissolving 14.4 mg β-glucuronidase (6.9 × 10 5 U g solid 
Sample collection and storage
Morning urine samples were collected from healthy volunteers aged 0-84 years on three consecutive days in 2016 in Henan Province, China (n = 301; 107 males, 194 females) and stored frozen at −70°C. The urine samples from all three days were mixed in a 1:1:1 ratio to make one sample prior to analyses. This study protocol was approved by the ethics committee of the China National Center for Food Safety Risk Assessment (no. 2016030063), and all the methods were performed in accordance with the approved guidelines and regulations. The study was fully explained to and informed consent was obtained from the adult participants and parents on behalf of the children who participated in the study.
Preparation of calibration standards and quality control samples
The calibration standard solutions were prepared by serial dilution of the mixed standard solution (1 μg/mL of each analyte) with methanol/water (50/50, v/v) to final concentrations of 0.1, 0.2, 0.5, 1, 2, 5, 10, and 20 ng/mL, with each solution containing 3 ng/mL 13 C-ZEN. Quality control (QC) samples at three concentrations (0.5, 2, and 20 ng/mL) were prepared by dilution of the mixed standard solution with blank urine samples, and were then stored at −70°C until use. QC samples were analyzed with each batch of study samples, and the measured values of the QC samples had to be within ±15% of the nominal values.
Sample preparation
Determination of free analytes Urine samples were thawed completely and centrifuged at 5000×g for 15 min at 4°C. The 13 C-ZEN internal standard was added to 1 mL of the supernatant at a concentration of 3 ng/mL, followed by a dilution with 1.5 mL of phosphate buffer (0.075 mol L −1 , pH 6.8). A 500 μL aliquot of the diluted sample was loaded onto an Oasis ® PRiME HLB μElution plate that had been preconditioned with 200 μL methanol followed by 200 μL water. The loaded samples were allowed to slowly pass through the sorbent under vacuum. The wells were sequentially washed with 200 μL of water and then 200 μL of 50% methanol to remove interfering compounds. After drying the plate, the analytes were eluted twice with 50 μL of methanol into a 96-well collection plate and then diluted with 100 μL of water prior to LC-MS/MS analysis.
Determination of total analytes After it had been thawed, centrifuged, and spiked with the 13 C-ZEN internal standard, 1 mL of the urine sample was digested with 1000 units of β-glucuronidase (dissolved in 1.5 mL phosphate buffer, 0.075 mol L −1 , pH 6.8) in a shaking water bath at 37°C for 18 h. Afterward, the digested samples were centrifuged again (5000×g; 15 min; 4°C). 500 μL of the supernatant were loaded onto an Oasis ® PRiME HLB μElution plate and then treated using exactly the same procedure as described above.
LC-MS/MS analysis
Analysis was carried out on an ACQUITY UPLC™ I-Class system (Waters) coupled to a Xevo ® TQ-S tandem quadrupole mass spectrometer (Waters). Operation of the instrument and data processing were performed using Masslynx software (version 4.1).
Chromatographic conditions
Chromatographic separation of ZEN and its five metabolites was achieved on a CORTECS™ UPLC® C18 column (2.1 × 100 mm, 1.6 μm) from Waters. A gradient mobile phase consisting of water (solvent A) and methanol/acetonitrile (80/20, v/v, solvent B) was applied at a flow rate of 0.4 mL/ min. The gradient program started with 50% B, which was ramped to 66% B in 4 min and then increased to 90% B within another 0.1 min. Next, the system was held at 90% B for 1.9 min and then reduced to 50% B within 0.1 min before being held for 1.9 min, leading to a total runtime of 6 min. The column temperature was kept at 40°C, the autosampler temperature was 4°C, and the injection volume was 10 μL.
Mass spectrometry conditions
A Xevo ® TQ-S tandem quadrupole mass spectrometer (Waters) equipped with an ESI source was used for mass detection and analysis. The MS/MS parameters in multiple reaction monitoring (MRM) mode were optimized for each analyte by continuously infusing standard solutions into the , 500°C), cone gas (nitrogen, 150 L h −1 ), and collision gas (argon, 0.15 mL/min).
Method validation
The method was validated in accordance with the guidelines defined by the EMEA [40] and FDA [41] . Linearity, selectivity, accuracy (method recovery, R M ), precision (intra-and interday variability), sensitivity (LOD and LOQ), and carryover were evaluated for ZEN and its five metabolites. R M was investigated at low (0.5 ng/mL), medium (1 ng/mL), and high (5 ng/mL) spiking levels in blank urine with 13 C 18 -ZEN internal standard correction. Evaluations of the apparent recovery (R A ), extraction recovery (R E ), and matrix effects (signal suppression/enhancement, SSE) were performed using three types of calibration curves [42] : a calibration curve prepared in the initial mobile phase (I) and matrix-matched calibration curves prepared by spiking before (II) and after (III) sample preparation. R E and R A were calculated by dividing the slope of calibration curve II by the slopes of calibration curves III and I, respectively. The SSE was determined by comparing the slope of calibration curve III with that of calibration curve I.
Statistical analysis
For statistical tests, the ZEN biomarker concentration was considered to be undetectable if it was half the value of the respective LOD or less. The total ZEN concentrations were natural-log-transformed for normality and then analyzed with the independent sample t-test and ANOVA to determine differences among different subgroups (age, gender). Statistical analysis was performed using SPSS, version 19 (SPSS, Chicago, IL, USA). A p value of <0.05 was considered statistically significant.
Results and discussion
Optimization of the MS/MS conditions
The MS/MS conditions were optimized through direct infusion of each individual compound. Ionization mode, capillary voltage, cone voltage, cone gas flow, source temperature, desolvation gas flow, and desolvation temperature were manually optimized in steps to achieve the most intense response of the precursor ion. ESI in negative mode with a capillary voltage of −2.
kV was selected, and [M-H]
− was chosen as the precursor ion for all analytes of interest. Afterwards, the collision energy (CE) was tuned to produce the most sensitive and stable product ion in the collision cell. For each compound of interest, two MRM transitions were selected and optimized-one for quantification and the other for identification, as listed in Table 1 .
Chromatographic separation
The high similarity of the structures of ZEN and its metabolites presents a challenge when attempting to separate them chromatographically. Baseline separation of the six target compounds was not achieved in previous works [30, 31, 33, 43, 44] . To obtain satisfactory UPLC separation, the main variables affecting the UPLC behavior were studied, including UPLC column, organic mobile phase (acetonitrile, methanol, or a mixture of acetonitrile and methanol), additives (ammonium acetate, ammonium formate, acetic acid, and formic acid) at different concentrations, and other parameters, such as the flow rate and gradient program. Among the tested columns, the CORTECS UPLC C18 column (2.1 mm × 100 mm, 1.6 μm) from Waters was found to provide the best resolution and peak shape for all the target compounds, and was consequently selected for subsequent studies. The organic modifier in the mobile phase markedly affected the chromatographic separation. The baseline separation of ZAN and α-ZEL was barely achieved when only methanol was used as the organic mobile phase. This was also the case in the separation of ZEN and ZAN when only acetonitrile was used as the mobile phase. However, the use of a mobile phase consisting of a mixture of methanol and acetonitrile (80/20, v/v) was found to lead to the complete separation of and sharp peaks for all the analytes in a 6-min gradient elution. Formic acid, ammonium formate, acetic acid, and ammonium acetate were evaluated as additives, but they did not aid the chromatographic separation and had only a very slight influence on the ion response. A representative chromatogram of a standard mixture of the target compounds at 0.2 ng mL −1 is shown in Fig. 1 .
Sample preparation
SPE is a powerful technique for sample preparation that has been widely used in ZEN analysis. However, the need for laborious evaporation and reconstitution steps has greatly limited its utility in fast analyses. To circumvent these obstacles, a 96-well PRiME HLB μElution plate was employed here for the first time to extract ZEN and its five metabolites from human urine samples. The main parameters, including loading, washing, and the elution buffer, were optimized to improve the efficiency, selectivity, and sensitivity. The urine matrix contains multiple endogenous components and metabolites that may cause complex background signals or increase the risk of clogging. Accordingly, sample predilution was necessary to achieve better retention of the target compound on the PRiME HLB μElution plate. After optimization, the urine samples were diluted 1.5-fold in phosphate buffer (0.075 mol L −1 , pH 6.8)-which is also the preferred solvent of β-glucuronidase (as recommended by the manufacturer)-and then loaded onto the μElution plate, resulting in complete retention of the analytes.
The selection of appropriate washing and elution buffers reduces the matrix effect and increases the recovery, so it is a crucial step. Urine samples spiked with 10 ng mL −1 of each analyte both before and after enzymatic hydrolysis were used for the optimization studies. After sample loading, a wash with pure water was necessary to remove salts and other water-soluble impurities. After that, buffers consisting of varying levels of methanol (5, 10, 20, 30, 40, 50, 75, 90 , and 100%, v/v) were applied to rinse the μElution plate, with the effluent collected and analyzed for the target compounds. As shown in Fig. 2 , all of the analytes were washed off with 50% methanol, and were completely eluted with 100% methanol. Therefore, 50% methanol and 100% methanol were adopted as the washing and elution buffers, respectively, allowing the maximum removal of interferences while stably retaining the analytes of interest. The effect of the elution volume was also evaluated, with volumes ranging from 25 to 200 μL (25, 50, 75, 100, 150, and 200 μL) tested in six replicates. High recoveries in the range 94~100% with RSDs of less than 6.0% were obtained for all analytes using 100 μL of elution buffer. No significant enhancement was observed upon increasing the elution volume beyond this level. Eventually, the best performance was obtained by washing with 200 μL of water and then 200 μL of 50% methanol and subsequently eluting twice with 50 μL of methanol, which yielded optimal extraction recoveries of 94~116% and matrix effects of 76.8~85.2% for all the analytes. The proposed 96-well μElution SPE protocol has several advantages over other approaches reported previously. The μElution plate contains only 2 mg of sorbent in each well, meaning that this method drastically reduces the consumption of samples and reagents as well as the contamination from packing materials. Additionally, unlike a Bdilute and shootm ethod [38, 39] , this procedure does not result in sample dilution, which can cause an apparent loss of sensitivity. To our knowledge, this is the first report of a method that enables high-throughput sample cleanup for the determination of ZEN and its metabolites, with each plate of urine samples (n = 96) processed within 1 h.
Method validation
The method was validated with reference to the guidelines specified by the EMEA and FDA in terms of linearity, selectivity, sensitivity (LOD and LOQ), accuracy, precision (intraand interday variability), and carryover.
The linearity was determined in the range from the LOQ up to 20.0 ng mL −1 by analyzing calibration standards at eight concentrations on three different days. The regression coefficients (R 2 ) of the calibration curves ranged from 0.9984 to 0.9999, with deviations of less than 12% for all measured concentrations. Standardized residuals from linear regression were also analyzed (see Fig. S1 in the BElectronic supplementary material,^ESM) and showed a random pattern. These results indicated good linear fits for all analytes.
The selectivity of the method was evaluated by comparing the chromatograms of six different blank urine samples with samples fortified with a mixture of analytes near the LOQ levels. As displayed in Fig. 3 , no endogenous interferences were observed at the retention time of each analyte or internal standard. In addition, baseline separation of the six target compounds further enhanced the selectivity of the method.
The LOD and LOQ of the method were determined using blank samples spiked at low levels, and corresponded to signal-to-noise (S/N) ratios of 3 and 10, respectively. The LOD and LOQ values for all analytes were 0.02-0.06 ng mL −1 and 0.05-0.2 ng mL
, respectively, with relative standard deviations (RSDs) at LOQ levels of less than 20% (n = 6) for all the analytes, as summarized in Table 2 . These results imply a significant increase in sensitivity compared with previously reported works [28, 31, 34] .
Accuracy and precision values were obtained from QC samples with three concentrations (0.5, 1.0, and 5.0 ng mL
) which were analyzed on three different days in six replicates. Values of the accuracy, expressed as the recoveries (R M , quantification with IS) of known amounts of the target compounds in QC samples, ranged between 87.9 and 100% at all concentration levels. The intraday and interday precisions (based on the RSD) were 1.2-6.9% and 2.7-10.7%, respectively (Table 3) . The extraction recovery (R E ) and the matrix effect (signal suppression/enhancement, SSE) were also investigated, as mentioned above. Good R E values ranging from 94.1% for ZEN to 116% for β-ZAL and good SSE values of between 76.8 and 85.2% for all the analytes were obtained. It is worth mentioning that even without IS compensation, the recoveries (apparent recoveries, R A ) were still satisfactory, ranging between 78.0 and 93.5% (Table 2) .
No sample-to-sample carryover was observed upon sequential injections of a high-concentration urine sample followed by three consecutive blanks.
Since ZEN-related urinary biomarkers occur in the low ng mL −1 range, sensitivity plays a critical role in ZEN exposure studies. Only a few data are currently available in this context.
A pilot study involving 27 urine samples from Spain did not confirm the presence of ZEN at a LOD of 3 ng/mL [33] . A recent study by Gerding et al. detected α-ZEL in 2.8% of 142 samples from Haiti, whereas no ZEN biomarkers were detected in 50 samples from Germany and in 95 samples from Bangladesh [39] . As stated by the authors, the low detection frequencies of ZEN and its metabolites, may be attributable to the high LOD of their approach. In our study, due to the high sensitivity of the present method, a high detection rate of 71.4% for the monitored ZEN biomarkers at concentrations of 0.02-3.7 ng mL −1 was achieved, which guarantees a reliable exposure study and risk assessment.
Human biomonitoring
Both the free and the total amounts of ZEN, α-ZEL, β-ZEL, ZAN, α-ΖAL, and β-ZAL in 301 human urine samples collected in Henan Province, China, were monitored using the developed method. ZEN, ZAN, α-ZEL, and β-ZEL were detected, whereas α-ΖAL and β-ZAL were not found in any of the analyzed samples. Chromatograms of the detected analytes in a naturally contaminated human urine sample are shown in Fig. 4 . Without β-glucuronidase hydrolysis, only 3.3% (n = 10/ 301) of the samples were found to be positive; the detection rates of ZEN, ZAN, α-ZEL, and β-ZEL were 1.3% (n = 4/ 301), 0.3% (n = 1/301), 1.3% (n = 4/301), and 1.0% (n = 3/ 301). ZEN was quantified in only one sample at a very low level: 0.05 ng mL −1 . The concentrations of the other detected compounds were all below their respective LOQs.
For the total amounts, much higher detection rates of ZEN (71.1%), ZAN (1.0%), α-ZEL (4.0%), and β-ZEL (21.9%) were obtained, with mean concentrations of 0.24, 0.017, 0.035, and 0.082 ng mL −1 , respectively (Table 4 ). In total, 28.6% of the samples were negative for all monitored ZEN biomarkers.
To further clarify the distribution of ZEN and its metabolites in the study population, the concentrations of these compounds in urine were analyzed by gender and age group (0-12, 13-18, 19-65, and > 65 years), as presented in Table 5 . The mean level of total ZEN was slightly higher in females (0.27 ± 0.39 ng mL ), but this difference did not reach statistical significance (P = 0.068). All four age groups were positive for ZEN and β-ZEL, while α-ZEL and ZAN were not observed in the elderly group. The mean level of total ZEN was highest in the adolescent group (age 13-18 years, 0.45 ± 0.44 ng mL −1 , P < 0.05). The other three groups had significantly lower amounts of total ZEN, with total ZEN decreasing in the following order: children (age ≤ 12 years, 0.27 ± 0.49 ng mL ), and then the elderly (age > 65 years, 0.14 ± 0.18 ng mL −1 ). However, there was no significant difference (P = 0.361, 0.221, and 0.066) among these three groups. The ng mL −1 levels of the analytes detected in human urine in this study were in good agreement with those reported previously, as summarized in Table 6 . Direct approaches that are designed to monitor ZEN, its metabolites (e.g., α-ZEL and β-ZEL), and glucuronide conjugates (e.g., ZEN-14-GlcA, α-ZEL-14-GlcA, β-ZEL-14-GlcA) [36, 38, 39, [45] [46] [47] [48] [49] [50] are generally less sensitive than indirect methods of determining ZEN and its metabolites after enzymatic treatment [32, 34, [51] [52] [53] [54] . Direct methods without hydrolysis and enrichment can only detect high concentrations (positive rates <8%), which may not be suitable for ZEN assessment. Biomonitoring of ZEN in Europe (Sweden [52] , Germany [53] , and Southern Italy [51] ) using indirect approaches has indicated very low ZEN exposure, with mean levels of total ZEN ranging from 0.05 to ND not detected (<LOD). When calculating means and medians, toxin concentrations <LOD were set to LOD/2 and toxin concentrations between the LOD and LOQ were set to LOQ/2 of the respective compound 0.23 ng/mL, whereas higher mean values of total ZEN were recorded in the US [32] as well as in some regions of South Africa [54] . The excretion patterns of ZEN varied widely among countries. Samples from Tunisian women had detectable ZEN, α-ΖAL, and β-ZAL [34] ; samples collected in South Africa and southern Italy were positive for ZEN, α-ΖEL, and β-ZEL [51, 54] ; and samples from New Jersey girls were found to be positive for ZEN and its five metabolites (α-ΖOL, β-ZEL, α-ΖAL, β-ZAL, and ZAN) [32] .
Probable daily intake of ZEN
Based on these findings, the probable daily intake (PDI) of ZEN was calculated from the urinary concentrations of ZENrelated biomarkers and published urinary excretion rates using the following formula:
where C is the biomarker concentration (μg L −1
), V is the daily urine excretion (L), W is the body weight (kg), and E is the excretion rate (%).
ZEN metabolite concentrations were adjusted to equivalent ZEN concentrations. A mean body weight of 60 kg and a mean daily urine excretion of 1.5 L were assumed [55] . Since no data on the human excretion of ZEN were available, the 24 h excretion rate measured in piglets (36.8%) was used to estimate the PDI in human [51, 56] . The mean PDI for ZEN was determined as 0.024 μg/kg bw, equivalent to approximately 5.0% of the PMTDI set by JECFA (0.5 μg/kg bw/ day) [6] or 10% of the TDI set by EFSA (0.25 μg/kg bw/ day) [7] . In another study, the urinary excretion rate of ZEN from a 27-year-old healthy male volunteer was determined as 9.4% (free ZEN and ZEN-GlcA combined = total ZEN) [57] . Accordingly, the mean PDI for ZEN was deduced as 0.061 μg/kg bw, around 12% of the PMTDI set by JECFA [6] or 24% of the TDI set by EFSA [7] . Both of these estimations indicate a low health risk from ZEN exposure in the Chinese subpopulation. However, it is important to bear in mind that since the excretion rate of ZEN calculated from large-scale human studies was unavailable, the PDIs calculated in this study were based on piglet excretion data or the excretion rate from a single human individual, meaning that those PDIs should be considered rough estimates rather than accurate risk assessments. ND not detected (<LOD). To calculate the mean values, concentrations <LOD were set to LOD/2 and concentrations between the LOD and LOQ were set to LOQ/2 of the respective compound
Conclusion
A rapid, sensitive, and selective method based on 96-well μElution SPE followed by UPLC-MS/MS has been developed and validated for the determination of ZEN and its metabolites in urine samples. The application of a PRiME HLB 96-well μElution plate permitted the rapid and simultaneous preparation of multiple samples without the need for evaporation and reconstitution steps. After detailed validation, the proposed method was implemented to determine the target compounds in human urine samples collected from healthy volunteers in China. ZEN, ZAN, α-ZEL, and β-ZEL were detected both with and without β-glucuronidase hydrolysis. Due to the improved sensitivity of the developed method, a high detection rate of 71.4% was obtained for ZEN-related biomarkers after enzyme hydrolysis. The mean PDI for ZEN was estimated to be 0.025 μg/kg bw, twenty times lower than the PMTDI set by JECFA, indicating a low health risk. Age-sex analysis of the participants indicated that the adolescent group had the highest exposure to ZEN. This well-tuned method delivered significantly improved throughput, sensitivity, and specificity as well as reductions in the time required, sample usage, and waste generated, making it a powerful alternative method for large-scale biosurveillance and for aiding with ZEN exposure risk assessment.
